Top Industry Leaders in the US Melanoma Market
Merck Sharp & Dohme (MSD) Receives FDA Approval for KEYTRUDA® (pembrolizumab) in Combination with YERVOY® (ipilimumab) for First-Line Treatment of Advanced/Unresectable Stage III Melanoma: This January 2024 approval expands treatment options for patients with advanced melanoma, offering a potentially more effective combination therapy.
Bristol-Myers Squibb (BMS) Announces Positive Phase 3 Results for Opdivo® (nivolumab) in Combination with RELIBRANT® (nivolumab + ipilimumab) for Adjuvant Treatment of Stage
III Melanoma: December 2023 development suggests the potential of this combination therapy to improve long-term survival outcomes in high-risk Stage III melanoma patients.
IO Biotech Partners with Regeneron to Develop Novel Immunotherapy for Melanoma: January 2024 collaboration combines expertise to accelerate the development of IOB-C100, a potential new class of immunotherapy targeting the LAG-3 immune checkpoint.
List of US Melanoma Key Companies in the Market
- Amgen Inc.
- Bristol-Myers Squibb
- Eisai Co. Ltd.
- Hoffmann-La Roche Ltd.
- Genentech Inc. Janssen Biotech Inc.
- and Novartis International AG. Pfizer
- Vical
- Ziopharm